A Prospective Trial of Nebulized Amikacin in the Treatment of Bronchiectasis Exacerbation
A Prospective Trial of Nebulized Amikacin in the Treatment of Bronchiectasis Exacerbation
About this item
Full title
Author / Creator
Ailiyaer, Yirepanjaing , Wang, Xiuxiu , Zhang, Yan , Li, Caiyu , Li, Tao , Qi, Qian and Li, Yu
Publisher
Basel, Switzerland: S. Karger AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: S. Karger AG
Subjects
More information
Scope and Contents
Contents
Background: Pseudomonas aeruginosa is the most common pathogenic bacteria in bronchiectasis (BE) patients. The availability and security of nebulized amikacin treatment are unknown. Objective: The purpose of this study was to explore the efficiency and adverse effects of nebulized amikacin treatment for 2 weeks, administered as intravenous therapy...
Alternative Titles
Full title
A Prospective Trial of Nebulized Amikacin in the Treatment of Bronchiectasis Exacerbation
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_crossref_primary_10_1159_000486134
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_crossref_primary_10_1159_000486134
Other Identifiers
ISSN
0025-7931
E-ISSN
1423-0356
DOI
10.1159/000486134
